Published in Br J Cancer on December 01, 1996
Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ (2000) 2.80
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer (2005) 1.94
Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer (2004) 1.62
Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer (1999) 1.26
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer (2007) 1.19
Lifetime physical activity and breast cancer risk in the Shanghai Breast Cancer Study. Br J Cancer (2001) 1.15
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat (2012) 1.09
Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer (2007) 1.08
Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res (2013) 1.06
Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer (2012) 1.06
Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg (2002) 1.03
Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg (2011) 0.97
Unique features of young age breast cancer and its management. J Breast Cancer (2014) 0.89
Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist (2014) 0.86
Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res (2010) 0.84
Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. Am J Pathol (2014) 0.83
Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol (2003) 0.83
Comparison of Clinical Features and Treatment Outcome of Breast Cancers in Young and Elderly Chinese Patients. Breast Care (Basel) (2011) 0.82
Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer (1999) 0.80
Reproductive factors and hormone receptor status among very young (<35 years) breast cancer patients. Oncotarget (2015) 0.79
Breast cancer in moroccan young women: a retrospective study. BMC Res Notes (2010) 0.79
Risk factors and natural history of breast cancer in younger Chinese women. World J Clin Oncol (2014) 0.78
Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis. Cancer Cell Int (2014) 0.78
Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast (2015) 0.77
Parallel routes of human carcinoma development: implications of the age-specific incidence data. PLoS One (2009) 0.77
Post-mastectomy radiotherapy can improve survival in breast cancer patients aged 35 years or younger with four or more positive nodes but not in one to three positive nodes. Ther Clin Risk Manag (2014) 0.77
Managing breast cancer in younger women: challenges and solutions. Breast Cancer (Dove Med Press) (2015) 0.76
Treatment of breast cancer in young women: do we need more aggressive therapies? J Thorac Dis (2013) 0.75
Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008. Biomed Res Int (2015) 0.75
Correlation of Tumoral Prognostic Factors by Sonoelastography Score in Patients to be Operated Due to Breast Cancer. Indian J Surg (2012) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A (1992) 8.87
Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol (1992) 6.13
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 6.03
Age as prognostic factor in premenopausal breast carcinoma. Lancet (1993) 4.31
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
Younger women with breast carcinoma have a poorer prognosis than older women. Cancer (1996) 3.54
P53 in tumour pathology: can we trust immunocytochemistry? J Pathol (1992) 3.00
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst (1992) 2.82
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol (1993) 2.27
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res (1990) 2.09
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr (1994) 1.79
Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer (1995) 1.54
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res (1989) 1.48
Histological grade of breast cancer in younger women. Lancet (1992) 1.46
Age as a prognostic factor in breast cancer. Cancer (1986) 1.46
p53 mutations occur in aggressive breast cancer. Cancer Res (1992) 1.43
Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer (1988) 1.32
Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer (1993) 1.28
Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer (1995) 1.27
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer (1989) 1.23
p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer (1994) 1.18
Breast cancer in women aged 30 and under. Cancer (1982) 1.13
Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer (1991) 1.13
p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res (1995) 1.09
Pathology and heredity of breast cancer in younger women. J Natl Cancer Inst Monogr (1994) 1.09
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
Histopathological characteristics and oestrogen receptor content in primary breast carcinoma. Virchows Arch A Pathol Anat Histol (1981) 1.03
The prognosis of breast carcinoma in women aged less than 40 years. Clin Radiol (1981) 0.98
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05
Association of human cyclin E with a periodic G1-S phase protein kinase. Science (1992) 5.98
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature (1996) 3.50
A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol (1998) 3.45
Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature (1999) 3.24
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene (1993) 2.99
Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci U S A (1993) 2.55
NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription. Mol Cell (1998) 2.33
Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev (1998) 2.30
The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene (2000) 2.15
A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A (1994) 1.95
Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol (1999) 1.91
Helminth infestations in immigrant children. Br Med J (1965) 1.87
Cyclin E, a potential prognostic marker for breast cancer. Cancer Res (1994) 1.82
Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer (1992) 1.80
Identification of an overlapping binding domain on Cdc20 for Mad2 and anaphase-promoting complex: model for spindle checkpoint regulation. Mol Cell Biol (2001) 1.70
Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene (1999) 1.64
Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. J Biol Chem (2001) 1.63
Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol (1999) 1.58
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 1.58
Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol Cell Biol (1998) 1.52
Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. J Virol (1994) 1.46
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells. Mol Cell Biol (1999) 1.34
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol (2000) 1.33
The adenovirus E1A-associated kinase consists of cyclin E-p33cdk2 and cyclin A-p33cdk2. J Virol (1993) 1.29
Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene (1998) 1.24
Efficacy of hepatitis B vaccine. J Soc Occup Med (1988) 1.19
Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol (1991) 1.17
Cyclin D3 is essential for megakaryocytopoiesis. Blood (1995) 1.15
Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat (1999) 1.15
Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J Exp Med (1996) 1.08
Fingerprinting cell lines: use of human hypervariable DNA probes to characterize mammalian cell cultures. Somat Cell Mol Genet (1988) 1.06
The use of a cloned bacterial gene to study mutation in mammalian cells. Mutat Res (1983) 1.06
Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer (1994) 1.05
Ataxia-telangiectasia: a human mutation giving high-frequency misrepair of DNA double-stranded scissions. Mol Biol Med (1986) 0.95
Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol (2001) 0.92
Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells. J Exp Med (1998) 0.91
Stat3-dependent induction of p19INK4D by IL-10 contributes to inhibition of macrophage proliferation. J Immunol (2000) 0.90
The use of recombinant DNA plasmids for the determination of DNA-repair and recombination in cultured mammalian cells. Br J Cancer Suppl (1984) 0.89
Decision making, beliefs, and attitudes toward hysterectomy: a focus group study with medically underserved women in Texas. J Womens Health Gend Based Med (2000) 0.87
DNA-mediated gene transfer into human diploid fibroblasts derived from normal and ataxia-telangiectasia donors: parameters for DNA transfer and properties of DNA transformants. Int J Radiat Biol Relat Stud Phys Chem Med (1984) 0.86
Vector-mediated DNA double-strand break repair analysis in normal, and radiation-sensitive, Chinese hamster V79 cells. Mutat Res (1988) 0.85
The effect of X-rays and ultraviolet light on DNA-mediated gene transfer in mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med (1984) 0.83
Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol (1999) 0.83
Molecular studies on the nature of the repair defect in ataxia-telangiectasia and their implications for cellular radiobiology. J Cell Sci Suppl (1987) 0.83
Examination of vectors with two dominant, selectable genes for DNA repair and mutation studies in mammalian cells. Mutat Res (1988) 0.82
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. J Med Chem (1988) 0.81
Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents. J Med Chem (1999) 0.81
Hysterectomy: beliefs and attitudes expressed by African-American women. Ethn Dis (2001) 0.80
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J Med Chem (1997) 0.79
Antipsychotic activity of substituted gamma-carbolines. J Med Chem (1987) 0.79
Development and validation of a screening test for 12 common mutations of the cystic fibrosis CFTR gene. Eur Respir J (1998) 0.76
The isolation and preliminary characterisation of a novel Escherichia coli mutant rorB with enhanced sensitivity to ionising radiation. Mol Gen Genet (1988) 0.76
The cloning of the rorB gene of Escherichia coli. Mol Gen Genet (1988) 0.75
The use of minisatellite variant repeat-polymerase chain reaction (MVR-PCR) to determine the source of saliva on a used postage stamp. J Forensic Sci (1994) 0.75
New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates. Bioorg Med Chem Lett (1998) 0.75
Prevalence of antibodies to Histoplasma capsulatum among Dutch speleologists. J Infect (1998) 0.75
Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns. J Pathol (1993) 0.75
Gorgoderina alobata sp.nov.(Trematoda: Gorgoderidae) from the toad Bombina variegata. Parasitology (1966) 0.75
Dominant mutation in mouse cells associated with resistance to Hoechst 33258 dye, but sensitivity to ultraviolet light and DNA base-damaging compounds. Somat Cell Mol Genet (1987) 0.75
Preparation and use of alkaline-phosphatase-conjugated oligonucleotide probes for single-locus and multilocus VNTR analysis. Methods Mol Biol (1998) 0.75